Novel Therapeutic Strategies for Targeting Glioblastoma Stem Cells
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 378
Special Issue Editors
Interests: glioblastoma; drug resistance; neurosteroids; Sp1
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Glioblastoma (GBM), derived from glial and astrocytes, is the most aggressive and lethal primary brain tumor in adults, classified as WHO grade 4. The standard treatment for glioblastoma is temozolomide (TMZ)-mediated chemotherapy conjugated with radiotherapy (CCRT) and surgery. Unfortunately, there is currently no effective treatment, and all patients experience recurrence after therapy. Due to its heterogeneity, the brain–blood barrier (BBB), and the immunosuppress ive tumor microenvironment, the average survival time from diagnosis is about 12–15 months. Glioblastoma stem cells (GSCs) are capable of self-renewal and tumor initiation upon repeated transplantation, contributing to tumor heterogeneity. Standard treatments often fail to fully eliminate GSCs, leading to disease recurrence. GSC research has emerged, offering new insights into GBM resistance and treatment. GSCs self-renew, drive tumor growth, and play a key role in tumor cell heterogeneity and the induction of systemic immunosuppression. Therefore, there is an urgent need for further research to understand the key mechanisms underlying glioblastoma's acquisition of chemotherapeutic resistance and identify novel biomarkers for more effective treatment strategies.
Dr. Tsung-I Hsu
Dr. Chih Jie Shen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- chemotherapeutic resistance
- glioblastoma stem cells
- immunosuppression
- brain–blood barrier
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
